Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Nanobiotix    NANO   FR0011341205

NANOBIOTIX (NANO)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

NANOBIOTIX : and the CLARA, partners of ETPN for the organization of the Nano World Cancer Day

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 08:40am CEST
Nanobiotix and the CLARA, partners of ETPN for the organization of the Nano World Cancer Day

01.28.2013

An event organized by the European Technology Platform of Nanomedicine in the framework of the World Cancer Day

Paris and Lyon, France, January 28th, 2013 - Nanobiotix and the Lyon Auvergne Rhône-Alpes Cancer Research Cluster (CLARA) today announce their participation to the European event on February the 1st organized by ETPN (European Technology Platform of Nanomedicine). Similar events will be organized in parallel across Europe: France, United Kingdom, Germany and Portugal. Nano World Cancer Day is an event organized by the ETPN highlighting the importance of nanomedicine research for cancer on the European level.

"How nanomedicine contributes to better cancer diagnostic and therapy"

Radiotherapy, chemotherapy and surgery are part of the therapeutic arsenal for patients with cancer. New technologies associated with nanoparticles could provide more effective solutions to personalize diagnoses and treat these diseases, while improving targeted drug delivery and reducing side effects and collateral damages on the body. These breakthrough therapies based on nanomedicine contribute to solving this paradigm and are already a reality, with concrete results, 60 nano-products on the market and more than 70 in the pipeline. Nanomedicine can go further in bringing new therapeutic mode of action into cells. For instance, nanoparticles can already be injected into the tumor and then be activated to produce physical effect and destroy cancer cells locally.

Across the parallel European press events, leading international actors in the field will introduce examples highlighting the key role of nanomedicine for cancer therapy, diagnoses and imaging. This year, these actors across Europe are:

National Cancer organizations: CLARA (FR), Comprehensive Cancer Center (Charité University Hospital) (DE), International Iberian Nanotechnology Laboratory (PT) and Instituto Português de Oncologia do Porto (PT).

SMEs: Nanobiotix (FR & DE).

Universities / Public laboratories: Thomas Jefferson University, Philadelphia, US (FR), Université Paris Sud, Institut Galien Paris-Sud / CNRS (FR), Ludwig-Maximilians University München (DE), Aachen University Hospital (DE), Universidad de Santiago de Compostela (Spain), University of Lisboa/ Faculty of Pharmacy (PT), Leeds University (UK).

 Leading local experts involved in the Paris event:

-          Dr. Amaury MARTIN, Secretary General of CLARA (Lyon Rhône-Alpes Auvergne Cancer Research Cluster), Lyon

-          Dr. Laurent LEVY, Vice Chairman ETPN, CEO of Nanobiotix, Paris

-          Pr. Bo LU, MD, Thomas Jefferson University Hospital, Professor in the Department of Radiation Oncology and Director of the department's Division of Molecular Radiation Biology, Philadelphia

-          Pr. Elias FATTAL, Paris Sud University, Institut Galien Paris-Sud, CNRS-UMR 8612, Faculty of Pharmacy, Châtenay-Malabry.

This conference will give an overview on nanomedicine for cancer: what are the key areas of research? What are the new methods of diagnosis? What are the new treatments in development? What are the first results? What are the products used every day?

Videos of the Paris event will be available on February the 4th 2013 for the World Cancer Day.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NANOBIOTIX
05/15NANOBIOTIX : 1st quarter earnings
CO
05/03NANOBIOTIX : Scientific Clinical | Nanobiotix partners with Weill Cornell Medici..
PU
05/03Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to ev..
GL
04/26NANOBIOTIX : Financial | NANOBIOTIX selected to enter Euronext’s Tech 40 L..
PU
04/17AACR ANNUAL MEETING 2018 : Nanobiotix presented preclinical data showing NBTXR3 ..
GL
04/10NANOBIOTIX : The university of texas md anderson cancer center and nanobiotix ha..
GL
03/30NANOBIOTIX : Nanobiotix 2017 Annual Results
AQ
03/27NANOBIOTIX SA : annual earnings release
01/22NANOBIOTIX : Scientific Clinical | presents first promising data from Phase I/II..
PU
01/22NANOBIOTIX presents first promising data from Phase I/II Liver Cancers trial ..
GL
More news
News from SeekingAlpha
2015NANOMETRICS : Well-Positioned In A Promising Industry 
2015Nanometrics' (NANO) CEO Timothy Stultz on Q4 2014 Results - Earnings Call Tra.. 
2015Nanometrics Incorporated (NANO) Q4 2014 Results - Earnings Call Webcast 
2015Nanometrics beats by $0.03, beats on revenue 
2015Notable earnings after Monday?s close 
Financials (€)
Sales 2018 11,1 M
EBIT 2018 -23,6 M
Net income 2018 -20,6 M
Finance 2018 3,20 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 22,4x
EV / Sales 2019 18,2x
Capitalization 252 M
Chart NANOBIOTIX
Duration : Period :
Nanobiotix Technical Analysis Chart | NANO | FR0011341205 | 4-Traders
Technical analysis trends NANOBIOTIX
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 29,8 €
Spread / Average Target 129%
EPS Revisions
Managers
NameTitle
Laurent Lévy Chief Executive Officer
Laurent Condomine Chairman-Supervisory Board
Alain Dostie Chief Operating Officer
Philippe Mauberna Chief Financial Officer
Elsa Borghi Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
NANOBIOTIX-12.41%296
CELLTRION, INC.--.--%31 351
IQVIA HOLDINGS INC3.81%20 375
LONZA GROUP1.41%19 687
INCYTE CORPORATION-29.64%14 126
NEKTAR THERAPEUTICS42.83%13 568